DelveInsight has launched a new report on Blastic Plasmacytoid Dendritic Cell Neoplasm Pipeline
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy of the bone marrow and blood that can affect other organs such as the lymph nodes, spleen, central nervous system, and skin. In fact, skin lesions are present in most patients with BPDCN. These skin lesions are often a deep purple color, and patients often develop multiple lesions. More men than women are diagnosed with BPDCN (~3:1 ratio), and it is most common in patients age 60 years and older. Although BPDCN occurs more frequently in the elderly, the tumor may occur in patients of any age, including pediatric patients.
Browse free sample copy- https://www.delveinsight.com/sample-request/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-malignancy-pipeline-insight
BK virus Infection Pipeline
BPDCN presents with features of both lymphoma and leukemia. Accurate diagnosis of this malignancy has been complicated by a number of factors, including shifting nomenclature over the years –BPDCN has been referred to as agranular CD4+ natural killer cell leukemia, blastic natural killer-cell leukemia/lymphoma and CD4+/CD56+ hematodermic neoplasm.1,4-6 As understanding of the biology and origin of this malignancy has improved, the World Health Organization (WHO) established the term blastic plasmacytoid dendritic cell neoplasm in 2008. BPDCN is currently classified by WHO as a distinct entity within the acute myeloid neoplasms and acute leukemias.
Emerging drugs included in the report
BK virus Infection Emerging Drugs
The dynamics of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending across the world and expected the launch of emerging therapies during the forecast period of 2020-2030. Companies across the globe are working towards the development of new treatment therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). There are currently many potential therapies for BPDCN in early-stage clinical trials that target CD123. A few of them have been described below.
BK virus Infection Report Scope
Table of content
1. Report Introduction
2. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy
3. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Current Treatment Patterns
4. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy – DelveInsight’s Analytical Perspective
6. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Late Stage Products (Phase-III)
7. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Discontinued Products
13. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Product Profiles
14. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Key Companies
15. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Key Products
16. Dormant and Discontinued Products
17. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Unmet Needs
18. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Future Perspectives
19. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Analyst Review
20. Appendix
21. Report Methodology
What are the report highlights?
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/